# Bioaegis Therapeutics Inc.

Canonical: https://abierto.us/vendors/bioaegis-therapeutics-inc-g2azac2pg7x3

- UEI: G2AZAC2PG7X3
- CAGE: 6QA91
- Location: Morristown, NJ
- Awards in window: 1 (1 transactions), $0 obligated, July 13, 2026 to July 13, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $0

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $0

## Competition

- Full and Open Competition: 1 awards

## Largest awards

- 75A50123C00067 (definitive contract): $0, Barda - Aspr / Daappo / Barda DCMA. Bioaegis: Plasma Gelsolin (Pgsn), an Abundant, Circulating Protein Modulates Inflammation While Also Enhancing Host Defenses by Stimulating the Uptake and Killing of Pathogens. Clinical Studies Have Consistently Shown PGSN Is Depleted in Severe I. https://www.usaspending.gov/award/CONT_AWD_75A50123C00067_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/bioaegis-therapeutics-inc-g2azac2pg7x3.